Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Multimorbidity in patients with monoclonal gammopathy of undetermined significance.

Publication ,  Journal Article
Epstein, MM; Zhou, Y; Castaneda-Avila, MA; Cohen, HJ
Published in: Int J Cancer
June 15, 2023

Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma, is present in over 5% of adults aged 70 and older, a population with a high prevalence of multimorbidity. MGUS is often diagnosed incidentally when patients seek care for unrelated conditions. Our study sought to examine patterns of multimorbidity among MGUS patients, as overall health may impact patient care and the prioritization of MGUS surveillance. We examined patterns of comorbidities in 429 patients diagnosed with MGUS (2007-2015) and 1287 matched controls. Twenty-seven conditions were defined at diagnosis/index date using algorithms developed by the Centers for Medicare and Medicaid Chronic Conditions Warehouse. Patterns of common comorbidities were identified individually, in dyads and triads, and compared between MGUS cases and controls. We conducted a latent class analysis to identify comorbidity patterns among cases only. We also examined comorbidity patterns among a subset of 32 MGUS cases who progressed to cancer during the study period. The most common comorbidities among both MGUS cases and controls included hypertension and hyperlipidemia. Anemia (cases: 43%; controls: 16%) and chronic kidney disease (CKD; cases: 36%; controls: 18%), and dyads and triads containing those conditions, were more common among cases. Latent class analysis identified three classes of comorbidity among MGUS cases: hypertension-hyperlipidemia plus anemia and CKD (31%); low comorbidity burden (17%); and hypertension-hyperlipidemia alone (52%). The higher prevalence among cases of anemia and CKD, which may be involved in the pathogenesis of, or surveillance for, MGUS, warrants additional investigation.

Duke Scholars

Published In

Int J Cancer

DOI

EISSN

1097-0215

Publication Date

June 15, 2023

Volume

152

Issue

12

Start / End Page

2485 / 2492

Location

United States

Related Subject Headings

  • United States
  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Multimorbidity
  • Monoclonal Gammopathy of Undetermined Significance
  • Medicare
  • Hypertension
  • Humans
  • Disease Progression
  • Aged, 80 and over
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Epstein, M. M., Zhou, Y., Castaneda-Avila, M. A., & Cohen, H. J. (2023). Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer, 152(12), 2485–2492. https://doi.org/10.1002/ijc.34476
Epstein, Mara M., Yanhua Zhou, Maira A. Castaneda-Avila, and Harvey J. Cohen. “Multimorbidity in patients with monoclonal gammopathy of undetermined significance.Int J Cancer 152, no. 12 (June 15, 2023): 2485–92. https://doi.org/10.1002/ijc.34476.
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer. 2023 Jun 15;152(12):2485–92.
Epstein, Mara M., et al. “Multimorbidity in patients with monoclonal gammopathy of undetermined significance.Int J Cancer, vol. 152, no. 12, June 2023, pp. 2485–92. Pubmed, doi:10.1002/ijc.34476.
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer. 2023 Jun 15;152(12):2485–2492.
Journal cover image

Published In

Int J Cancer

DOI

EISSN

1097-0215

Publication Date

June 15, 2023

Volume

152

Issue

12

Start / End Page

2485 / 2492

Location

United States

Related Subject Headings

  • United States
  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Multimorbidity
  • Monoclonal Gammopathy of Undetermined Significance
  • Medicare
  • Hypertension
  • Humans
  • Disease Progression
  • Aged, 80 and over